Selenium, as Sodium Selenite, in the Treatment of Septic Shock

• Status: Completed
• Trial end date: 2005-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Septic shock is a frequent syndrome with a 45% mortality rate despite intensive care unit (ICU) care, where free radicals may play a key role, and a >40% decrease in plasma selenium concentration is observed. Selenium is a trace element with both indirect enzymatic anti-oxidant, and direct oxidant properties. High dose of sodium selenite administration could increase antioxidant cells capacities, and reduce inflammation by a direct paradoxical pro-oxidative effect. We conduct a study to evaluate the effects of selenium treatment in comparison to placebo, in septic shock patients. Efficacy will be evaluated by the weaning time of catecholamines.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier de Meaux
• Collaborator: Ministry of Health, France
• Treatments: Selenious Acid; Selenium; Sodium Selenite

Criteria

Inclusion Criteria:

• Hospitalization in ICU

• Severe documented infection

• Ventilation

• Circulatory failure requiring high dose of catecholamine

• IGS II score >25 at inclusion

• Informed written consent

Exclusion Criteria:

• Pregnancy

• End phase chronic disease

• Limitation of care

• Shock due to an urinary infection without bacteriemia

• Peritonitis related to peritoneal dialysis or trauma

• Preliminary circulatory failure

• Participating to another clinical trial